Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Author information

Affiliations

  • 1. Department of Pathology, Centre G-F Leclerc, Dijon 21000, France.
      Authors
    • Arnould L 1
    (1 author)

ORCIDs linked to this article

British Journal of Cancer, 01 Jan 2006, 94(2):259-267
https://doi.org/10.1038/sj.bjc.6602930 PMID: 16404427 PMCID: PMC2361112

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

A comment on this article appears in "Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer." Br J Cancer. 2006 May 22;94(10):1550-2.

Abstract 

This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were treated with trastuzumab plus docetaxel. Pathological complete and partial responses were documented for nine (39%) and 14 (61%) patients, respectively. Case-matched controls comprised patients treated with docetaxel-based PST without trastuzumab (D; n=23) or PST without docetaxel or trastuzumab (non-taxane, non-trastuzumab, NT-NT; n=23). All surgical specimens were blind-analysed by two independent pathologists, with immunohistochemical evaluation of B and T lymphocytes, macrophages, dendritic cells and natural killer (NK) cells. Potential cytolytic cells were stained for Granzyme B and TiA1. HER2 expression was also evaluated in residual tumour cells. Trastuzumab treatment was associated with significantly increased numbers of tumour-associated NK cells and increased lymphocyte expression of Granzyme B and TiA1 compared with controls. This study supports an in vivo role for immune (particularly NK cell) responses in the mechanism of trastuzumab action in breast cancer. These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer.

Free full text 

Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2006 Jan 30; 94(2): 259–267.
Published online 2006 Jan 10. https://doi.org/10.1038/sj.bjc.6602930
PMCID: PMC2361112
PMID: 16404427

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

L Arnould,1,10,* M Gelly,1 F Penault-Llorca,2 L Benoit,3 F Bonnetain,4 C Migeon,5 V Cabaret,6 V Fermeaux,7 P Bertheau,8 J Garnier,9 J-F Jeannin,10 and B Coudert11
Author information Article notes Copyright and License information Disclaimer
Abstract

This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were treated with trastuzumab plus docetaxel. Pathological complete and partial responses were documented for nine (39%) and 14 (61%) patients, respectively. Case-matched controls comprised patients treated with docetaxel-based PST without trastuzumab (D; n=23) or PST without docetaxel or trastuzumab (non-taxane, non-trastuzumab, NT–NT; n=23). All surgical specimens were blind-analysed by two independent pathologists, with immunohistochemical evaluation of B and T lymphocytes, macrophages, dendritic cells and natural killer (NK) cells. Potential cytolytic cells were stained for Granzyme B and TiA1. HER2 expression was also evaluated in residual tumour cells. Trastuzumab treatment was associated with significantly increased numbers of tumour-associated NK cells and increased lymphocyte expression of Granzyme B and TiA1 compared with controls. This study supports an in vivo role for immune (particularly NK cell) responses in the mechanism of trastuzumab action in breast cancer. These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer.

Keywords: primary systemic therapy, trastuzumab, ADCC, MoA

The human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family that plays an important role in promoting oncogenic transformation and tumour growth (Slamon et al, 1987). Approximately 25–30% of patients with breast cancer overexpress HER2 and this overexpression is correlated with gene amplification and poor clinical outcome (King et al, 1985; Slamon et al, 1987, 1989; van de Vijver et al, 1988; Gusterson et al, 1992; Hynes and Stern, 1994).

Trastuzumab (Herceptin®; F Hoffmann-La Roche, Basel, Switzerland) selectively targets HER2 and is approved for the treatment of women with HER2-overexpressing metastatic breast cancer (MBC). Trastuzumab demonstrates favourable efficacy both as a single agent (Cobleigh et al, 1999; Vogel et al, 2002) and in combination with cytotoxic chemotherapy (Pegram et al, 1999; Slamon et al, 2001; Marty et al, 2005). The proposed mechanisms of action of trastuzumab include enhancement of HER2 degradation (Molina et al, 2001), inhibition of cell cycle progression via inhibition of the mitogen-activated protein kinase pathway (Le et al, 2003; Jackson et al, 2004), and suppression of the antiapoptotic phosphatidylinositol 3-kinase and Akt pathways (Yakes et al, 2002; Mohsin et al, 2005). In addition, there is evidence supporting a role for trastuzumab in mediating antibody-dependent cellular cytotoxicity (ADCC) (Cooley et al, 1999; Clynes et al, 2000; Carson et al, 2001; Repka et al, 2003; Gennari et al, 2004). Mechanisms of action of trastuzumab demonstrated in vitro in HER2-overexpressing cells are not always confirmed in in vivo studies (Mohsin et al, 2005).

Trastuzumab-based therapy has been shown to be effective in the neoadjuvant (primary systemic therapy (PST)) setting (Bines et al, 2003; Burstein et al, 2003; Schiffhauer et al, 2003; Van Pelt et al, 2003; Baselga et al, 2004; Buzdar et al, 2005). This immunohistological analysis, which was undertaken as part of a clinical study, aimed to evaluate the immune response to trastuzumab-based PST within tumours obtained from women with locally advanced breast cancer.

PATIENTS AND METHODS

Patients

Between March 2001 and December 2003, 33 women (age 18–65 years) with stage II/III, unilateral, non-inflammatory, operable breast cancer requiring a mastectomy (but who wished to conserve the breast) were enrolled in the open-label, multicentre, phase II TAXHER01 trial (Coudert et al, 2005). All patients had HER2-positive (immunohistochemistry (IHC) 3+ or fluorescence in-situ hybridisation (FISH)-positive) breast cancer and were treated with PST consisting of six cycles of docetaxel (100 mg m−2 60-min intravenous (i.v.) infusion every 3 weeks) and trastuzumab (4 mg kg−1 90-min i.v. infusion 1 day before the first dose of docetaxel, and thereafter at a dose of 2 mg kg−1 weekly for 17 weeks). All patients underwent surgery 3 weeks after the last cycle of docetaxel and trastuzumab.

In all, 46 patients with breast cancer enrolled in the GIREC01 trial (Luporsi et al, 2000) were used as matched controls. Of these patients, 23 received anthracycline-based, non-taxane, non-trastuzumab-containing PST (NT–NT; six cycles), and 23 received docetaxel-based, non-trastuzumab-containing therapy (D; six cycles). Tumours from 15 patients in the control group were HER2 positive, five in the NT–NT group and 10 in the D group. The treatment group (TAXHER01) was case-matched with the two control groups in terms of pathologic tumour and node response. Due to the lack of patients treated preoperatively with such a combination, it was not possible to have control groups with trastuzumab plus a non-taxane chemotherapy or trastuzumab alone.

Both clinical studies were conducted in accordance with the Helsinki Declaration and approved by an independent ethics committee. Written informed consent was obtained from all patients prior to enrolment.

Microscopic evaluation of the pathologic response to PST

Microtome sections obtained from surgical tissue were fixed in 10% neutral buffered formaldehyde solution or Bouin fluid (Richard-Allan Scientific, Kalamazoo, MI, USA), embedded in paraffin wax, and stained with haematoxylin, eosin, and saffron. Pathologic response to PST was assessed according to the Sataloff classification (Sataloff et al, 1995). Tumour samples containing no tumour nodules or tumours with residual area <2 mm in diameter were classified as TA. Tumour samples with residual tumour area <0.2 mm in diameter in lymph nodes, not classified as micrometastases in the UCC classification (Singletary et al, 2002; Singletary and Greene, 2003), were classified as NA.

Microscopic and immunohistologic analyses

Immunohistochemical evaluation was performed on one paraffin block that was considered to correspond morphologically with the tumour response area, using the biotin–streptavidin complex (ABC) technique (StreptABC complex/HRP Duet; Dako, Glostrup, Denmark) and the following primary antibodies: B lymphocytes (CD20 (L26, 1 out of 50; Dako, Glostrup, Denmark)); T lymphocytes (CD3 (F7.2.38, 1 out of 25; Dako, Glostrup, Denmark); CD4 (NCL-CD4-368, 1 out of 150; Novocastra, Newcastle, UK); CD8 (C8/144B, 1 out of 25; Dako, Glostrup, Denmark)); macrophages (CD68 (PG-M1, 1 out of 50; Dako, Glostrup, Denmark)); dendritic cells (PS100 (S100, 1 out of 500; Dako, Glostrup, Denmark); CD1a (010, 1 out of 40; Dako, Glostrup, Denmark)); HLA-DR-expressing cells (HLA-DR (TAL.1B5, 1 out of 20;Dako, Glostrup, Denmark)) and natural killer (NK) cells (CD56 (1B6, 1 out of 50; Novocastra, Newcastle, UK); NK1 (NK1, 1 out of 75; Dako, Glostrup, Denmark)). Potential cytolytic cells were stained with Granzyme B (GrB-7, 1 out of 25; Dako, Glostrup, Denmark) and TiA1 (2G9, 1 out of 50; Immunotech, Marseille, France). TiA1 is a 17 kDa cytoplasmic granule-associated protein expressed in cells possessing, like Granzyme B-expressing cells, potential cytolytic activity. If residual tumour cells were identified, immunohistochemical analysis of HER2 expression was performed (A485, 1 out of 1600; Dako, Glostrup, Denmark).

Two pathologists, blinded to study treatment, performed independent IHC evaluations of all tumour samples. Infiltrating cells were analysed in four separate locations on each slide: diffuse (isolated cells distributed all around the area of tumour regression), foci (organised in nodules), around (a small rim around the tumour nodules in contact with residual tumour cells), and inside (penetrating inside tumour nodules between residual tumour cells). In each location on the slide, the number of stained cells was analysed using a semiquantitative ordinal scale ranging from 0 to 4 (0, +/−, ++, +++). For each antibody, this scale was established after the analysis of more than 15 cases and concerned only the number of infiltrating stained cells, whatever the intensity of the staining. The results of the analyses conducted by each independent pathologist were subsequently compared. For each location, all cases in which scores differed by more than one point on the semiquantitative scale were re-examined and a consensus score was reached.

Statistical analysis

Slides were unblinded immediately prior to the statistical analysis. Statistical analyses were performed with a 5% type I (bilateral) error using the Stata 8.2 software package (StataCorp LP, TX, USA). The mean (standard deviation (s.d.)) number of stained cells was calculated for each data group (treatment group and two control groups). A two-sided Wilcoxon rank-sum (Mann–Whitney) test was used to determine differences between the groups.

A subgroup analysis was also performed to exclude potential treatment-independent, HER2 overexpression-related effects if values obtained for the treatment and control groups were significantly different. This analysis compared the results from the treatment group (TAXHER01) with those from HER2-overexpressing subgroups of the control groups (HER2 control, n=15). Due to multiple testing, a type I error adjustment was applied to this subgroup analysis (significance level P[less-than-or-eq, slant]0.01).

RESULTS

Three patients from the TAXHER01 trial withdrew from the study due to toxicity. Seven additional cases were not available for immunohistochemical analysis because of fixative problems or false-positive HER2 overexpression. The final analysis was therefore performed on the surgical specimens from 23 patients. The control group from the GIREC01 trial comprised specimens obtained from 46 (23 NT–NT and 23 D) patients, 15 of whom had tumours that were HER2 positive (5 NT–NT and 10 D). Patient characteristic data are shown in Table 1.

Table 1

Patient characteristics
  TAXHER01 (N=23) NT-NT (N=23) D (N=23)
Age, mean (range)45 (24–64)44.5 (27–60)47.5 (27–65)
    
Clinical tumour stage
T2141613
T39710
    
Clinical nodal status
N0101010
N1131313
    
Scarff-Bloom-Richardson tumour grade
I131
II998
III131114
    
Tumour hormone-receptor status
Positive131213
Negative101110

NT-NT=non-taxane, non-trastuzumab; D=docetaxel.

Pathologic response

After surgery, nine tumours in the TAXHER01 group (39%) were classified as demonstrating a pathological complete response (pCR; TA/NA or TA/NB), with two demonstrating residual tumour aggregates <2 mm in diameter. One other tumour was classified as TA/NC (no residual tumour in the breast, but residual tumour cells in the lymph nodes). The remaining 13 tumours displayed partial (pPR; TB or TC) or absent (TD) pathological responses. Eight tumours were classified as TB (residual tumour size 0.4–1.5 cm (mean 0.80 cm)), four were classified as TC (residual tumour size 1.5–7.0 cm (mean 3.2 cm)), and only one tumour was classified as TD (residual tumour size 6 cm). As tumour responses in the two control groups were matched to those in the treatment group, there were equivalent numbers of patients with complete, partial, or absent pathological responses in the 23 tumours treated in the D and NT–NT groups.

Areas of tumour response were associated with fibrosis, myxoedema, and macrophage/lymphocyte infiltration. Necrosis or infiltration with polynuclear neutrophils was not observed.

Immunohistochemical analysis

Immune cell infiltration

Comparison of the three groups revealed that higher expression of PS100 and HLA-DR was observed in the TAXHER01 and NT–NT groups as compared with the D group, although the difference was not statistically significant (Table 2).

Table 2

Immune cell infiltration into breast tumours following PST
  TAXHER01 (n=23) Control (n=46) D (n=23) NT–NT (n=23) TAXHER01 vs control D vs NT–NT
Antibodies location Mean (s.d.) staining intensity score P-value
CD20
Diffuse1.61 (1.3)1.10 (0.9)1.09 (0.9)1.04 (0.9)0.08020.8272
Around1.13 (1.5)0.52 (1.2)0.39 (1.0)0.65 (1.3)0.05980.4432
Inside0.43 (0.9)0.33 (0.9)0.04 (0.1)0.61 (1.2)0.40130.0686
Foci3.13 (1.2)1.70 (1.5)1.61 (1.4)1.78 (1.7) 0.0005 0.8391
       
CD3
Diffuse2.09 (1.4)1.42 (1.0)1.35 (0.9)1.50 (1.1) 0.0386 0.7389
Around1.52 (1.6)0.82 (1.5)0.70 (1.4)0.95 (1.5)0.05600.5014
Inside0.65 (1.2)0.47 (1.0)0.39 (0.9)0.55 (1.1)0.47340.5014
Foci2.87 (1.1)1.64 (1.2)1.43 (1.1)1.86 (1.4) 0.0001 0.2116
       
CD4
Diffuse1.04 (1.3)0.91 (0.9)0.91 (0.8)0.91 (0.9)0.76050.8776
Around1.35 (1.7)0.46 (1.0)0.39 (1.0)0.52 (1.1) 0.0270 0.5223
Inside0.35 (0.7)0.04 (0.2)0.00 (0.0)0.09 (0.3) 0.0209 0.1527
Foci2.17 (1.3)1.30 (1.3)1.65 (1.2)0.96 (1.3) 0.0107 0.0627
       
CD8
Diffuse1.96 (1.5)1.87 (0.9)1.96 (0.9)1.78 (1.0)0.56700.4738
Around1.56 (1.7)0.76 (1.4)0.52 (1.2)1.00 (1.5) 0.0460 0.1997
Inside1.22 (1.3)0.78 (1.1)0.65 (1.1)0.91 (1.0)0.19990.2454
Foci2.39 (1.6)1.50 (1.4)1.43 (1.3)1.56 (1.5) 0.0160 0.6410
       
CD68
Diffuse1.91 (1.3)2.30 (1.2)2.43 (1.2)2.17 (1.2)0.30360.5172
Around0.91 (1.6)0.54 (1.3)0.48 (1.3)0.61 (1.3)0.35940.5271
Inside0.56 (1.0)0.39 (0.8)0.26 (0.7)0.52 (0.8)0.56760.1883
Foci0.09 (0.4)0.00 (0.0)0.00 (0.0)0.00 (0.0)0.1573 
       
PS100
Diffuse1.70 (1.3)1.59 (1.2)1.48 (0.9)1.70 (1.5)0.70680.9540
Around1.35 (1.6)0.63 (1.3)0.30 (0.9)0.96 (1.5) 0.0557 0.1234
Inside0.61 (1.3)0.37 (0.9)0.13 (0.6)0.61 (1.1)0.4579 0.0488
Foci1.74 (1.7)1.1 (1.4)0.78 (1.2)1.35 (1.6) 0.0691 0.2202
       
CD1a
Diffuse1.61 (0.8)1.83 (0.9)1.74 (0.8)1.91 (0.9)0.37880.4385
Around0.39 (0.7)0.41 (1.0)0.39 (1.0)0.43 (1.0)0.55560.5378
Inside0.26 (0.5)0.28 (0.9)0.17 (0.7)0.39 (1.0)0.31800.5968
Foci0.00 (0.0)0.00 (0.0)0.00 (0.0)0.00 (0.0)  
       
HLA-DR
Diffuse2.09 (1.0)2.33 (1.0)2.26 (0.8)2.39 (1.1)0.53700.4624
Around1.70 (1.7)1.04 (1.5)0.83 (1.5)1.26 (1.5)0.11510.2308
Inside0.91 (1.2)0.72 (1.0)0.39 (0.8)1.04 (1.1)0.5778 0.0258
Foci2.30 (1.1)1.54 (1.3)1.70 (1.3)1.39 (1.3) 0.0335 0.4649
       
CD56 a
Diffuse0.83 (1.0)0.74 (0.8)0.87 (0.8)0.61 (0.8)1.00000.2125
Around1.00 (1.5)0.57 (1.1)0.43 (1.0)0.70 (1.2)0.2468a0.3175
Inside0.30 (0.7)0.11 (0.4)0.09 (0.4)0.13 (0.3)0.2520a0.3336
Foci0.26 (0.7)0.28 (0.8)0.26 (0.9)0.30 (0.7)0.97390.4756
       
NK1
Diffuse1.45 (1.4)1.20 (0.9)1.39 (0.8)1.00 (0.9)0.58640.1349
Around1.64 (1.6)0.41 (1.0)0.43 (1.1)0.39 (1.0) 0.0003 0.7919
Inside0.82 (1.3)0.30 (0.8)0.17 (0.7)0.43 (1.0) 0.0438 0.2251
Foci2.01 (1.4)0.74 (1.1)0.83 (1.1)0.65 (1.1) 0.0003 0.4678
       
TiA1
Diffuse1.13 (1.3)1.30 (1.0)1.30 (0.9)1.30 (1.1)0.44110.9816
Around1.43 (1.7)0.85 (1.5)0.61 (1.4)1.1 (1.6)0.19820.3113
Inside0.65 (1.0)0.26 (0.8)0.17 (0.7)0.35 (0.9) 0.0370 0.3878
Foci1.00 (1.0)0.54 (1.0)0.65 (1.2)0.43 (0.8)0.21810.5759
       
Granzyme B
Diffuse0.26 (0.7)0.26 (0.4)0.30 (0.5)0.22 (0.4)0.48700.5066
Around0.83 (1.3)0.28 (0.9)0.22 (0.9)0.35 (0.9) 0.0324 0.4087
Inside0.22 (0.7)0.07 (0.3)0.13 (0.5)0.00 (0.0)0.19260.1528
Foci0.52 (0.8)0.33 (0.7)0.13 (0.3)0.52 (0.9)0.25710.1126

NT–NT, anthracycline-based PST that does not include a taxane or trastuzumab; D, docetaxel-based PST.

For diffuse/around/inside/foci, scores range from 0 to 4.

aStaining with CD56 was less intense and difficult to quantify.

Significant if P<0.05. Bold values signify their importance in the results and the discussion.

Comparison of pooled results from the D and NT–NT groups with TAXHER01 showed greater numbers of immunocompetent cells in the TAXHER01 specimens compared with controls. B lymphocytes were more numerous in the TAXHER01 specimens at the four locations analysed, but the difference was only significant in the foci infiltrates. T lymphocytes (CD3, CD4, and CD8) were also more numerous in the TAXHER01 specimens; differences between TAXHER01 and control specimens were statistically significant in the diffuse and foci infiltrates for CD3, in the foci, inside and around infiltrates for CD4, and in the foci and around infiltrates for CD8. Tumour area infiltration by macrophages (CD68) was not statistically different between the TAXHER01 and control groups. Dendritic cells (PS100, CD1a) and HLA-DR-expressing inflammatory cells appeared to be slightly more abundant in the TAXHER01 samples, but, because of the differences between the two control groups, results are difficult to interpret (Table 2). Figures 1, ​,2,2, ​,33 and ​and44 show immunohistochemical staining of cells that are able to undergo ADCC mechanisms, and that have potential cytotoxic activity, from both the TAXHER01 group and the case-matched control groups. Natural killer cell numbers were increased in the around (Figure 1A) and inside infiltrates of residual tumour cells in TAXHER01 specimens compared with controls (statistically significant by NK1 staining, Figure 1). In addition, there were statistically more NK1-positive cells in foci infiltrates from TAXHER01 specimens compared with controls. Staining with CD56 is notoriously difficult and was therefore less intense than other methods and consequently difficult to quantify (Figure 2). Finally, cytotoxic molecule (Granzymze B and TiA1)-expressing cells were more numerous in contact with the residual tumour cells in TAXHER01 specimens compared with controls (Figures 3 and ​and4),4), with statistically significant differences demonstrated for Granzyme B (around) and for TiA1 (inside).

An external file that holds a picture, illustration, etc. Object name is 94-6602930f1.jpg

Immunohistochemical staining with NK1. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with NK1. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.

An external file that holds a picture, illustration, etc. Object name is 94-6602930f2.jpg

Immunohistochemical staining with CD56. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B) both stained with CD56. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.

An external file that holds a picture, illustration, etc. Object name is 94-6602930f3.jpg

Immunohistochemical staining with Granzyme B. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with Granzyme B. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.

An external file that holds a picture, illustration, etc. Object name is 94-6602930f4.jpg

Immunohistochemical staining with TiA1. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with TiA1. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.

Influence of HER2 overexpression on immune cell infiltration

To evaluate the potential treatment-independent effects of HER2 overexpression, immune cell infiltration in TAXHER01 tumours was compared with that in HER2-positive tumour subgroups of the control groups (HER2 control, n=15) (Table 3). While the number of cases in the HER2-positive tumour subgroup is low, the comparison between the TAXHER01 treatment group and this subgroup is favoured as these tumour samples were obtained from a clinical trial and hence had validated clinical and pathological data.

Table 3

Immune cell infiltration into HER2-overexpressing breast tumours following PST
  TAXHER01 (n=23) HER2 control (n=15) TAXHER01 vs control
Antibodies location Mean (s.d.) staining intensity score P-value
CD20
Diffuse1.61 (1.27)1.53 (1.19)0.8525
Around1.13 (1.52)0.40 (1.06)0.1036
Inside0.43 (0.94)0.20 (0.77)0.2488
Foci3.13 (1.18)2.13 (1.64)0.0840
    
CD3
Diffuse2.09 (1.41)1.80 (1.08)0.3734
Around1.52 (1.62)0.93 (1.44)0.2352
Inside0.65 (1.19)0.40 (0.74)0.6948
Foci2.87 (1.06)1.67 (1.40) 0.0046
    
CD4
Diffuse1.04 (1.33)0.87 (0.91)0.9618
Around1.35 (1.67)0.33 (0.72)0.0605
Inside0.35 (0.71)0.00 (0.00)0.0565
Foci2.17 (1.27)1.53 (1.30)0.1423
    
CD8
Diffuse1.96 (1.49)2.00 (1.00)0.9259
Around1.56 (1.70)0.80 (1.21)0.1342
Inside1.22 (1.31)0.67 (0.90)0.2039
Foci2.39 (1.62)2.33 (1.17)0.5882
    
CD68
Diffuse1.91 (1.31)3.13 (0.74) 0.0037
Around0.91 (1.59)0.00 (0.00)0.0341
Inside0.56 (0.99)0.33 (0.72)0.5592
Foci0.09 (0.42)0.00 (0.00)0.4193
    
PS100
Diffuse1.70 (1.29)2.00 (1.07)0.4600
Around1.35 (1.64)0.67 (1.29)0.2253
Inside0.61 (1.31)0.20 (1.56)0.4394
Foci1.74 (1.66)1.27 (1.53)0.3246
    
CD1a
Diffuse1.61 (0.78)1.80 (0.77)0.4990
Around0.39 (0.72)0.40 (0.91)0.7634
Inside0.26 (0.54)0.27 (0.80)0.5800
Foci0.00 (0.00)0.00 (0.00) 
    
HLA-DR
Diffuse2.09 (1.04)2.40 (0.91)0.5216
Around1.69 (1.72)0.73 (1.33)0.0786
Inside0.91 (1.16)0.53 (0.92)0.3676
Foci2.30 (1.15)2.00 (1.20)0.5809
    
CD56 a
Diffuse0.83 (1.03)0.67 (0.82)0.7562
Around1.00 (1.51)0.80 (1.08)0.8762
Inside0.30 (0.70)0.20 (0.56)0.7062
Foci0.26 (0.69)0.53 (1.12)0.4797
    
NK1
Diffuse1.45 (1.40)1.20 (0.86)0.5737
Around1.64 (1.56)0.40 (1.12) 0.0097
Inside0.82 (1.26)0.20 (0.77) 0.0532
Foci2.05 (1.43)1.07 (1.16) 0.0303
    
TiA1
Diffuse1.13 (1.32)1.67 (0.82)0.1448
Around1.43 (1.73)0.53 (1.41)0.0942
Inside0.65 (1.03)0.07 (0.26) 0.0407
Foci1.00 (1.20)1.00 (1.51)0.8120
    
Granzyme B
Diffuse0.26 (0.69)0.33 (0.49)0.3126
Around0.82 (1.33)0.27 (0.80)0.1374
Inside0.22 (0.67)0.07 (0.26)0.5188
Foci0.52 (0.85)0.27 (0.80)0.1758

NT–NT, anthracycline-based PST that does not include a taxane or trastuzumab; D, docetaxel-based PST.

For diffuse/around/inside/foci, scores range from 0 to 4.

aStaining with CD56 was less intense and difficult to quantify. Significant if P<0.05. Bold values signify their importance in the results and the discussion.

The limited number of cases in this subanalysis precludes definitive conclusions. There was a trend towards increased lymphocyte numbers (CD20, CD3, CD4, and CD8) in the TAXHER01 group compared with HER2 controls. Diffuse macrophage infiltration (CD68) was significantly increased in HER2 controls compared with the treatment group, but increased macrophage infiltration was observed around the residual tumours in the treatment group. There was also a trend towards increased dendritic cell (PS100, CD1a) and HLA-DR-expressing cell infiltration in TAXHER01 tumours. Natural killer and cytotoxic cells (TiA1 or Granzyme B) tended to be more numerous in contact with residual tumour cells in the TAXHER01 tumours, with significant differences demonstrated for TiA1 (P<0.05) and NK1 staining (P<0.01).

Correlation of tumour response with level of immune cell infiltration

To further characterise the role of immune cells on tumour regression, immune cell infiltration in TAXHER01 tumours demonstrating a partial response (TB) was compared with that in TAXHER01 tumours demonstrating a poor or absent response (TC and TD). For almost all markers (except CD8, CD68, and PS100), there was a trend towards increased cell infiltration in responsive tumours (Table 4). This was particularly evident for NK (CD56 and NK1) and cytotoxic markers (Granzyme B and TiA1) inside residual tumour aggregates. With the exception of TiA1, these differences were not statistically significant.

Table 4

Immune cell infiltration into breast tumours following trastuzumab-based PST by response status
  TAXHER01 TB (n=8) TAXHER01 TC/TD (n=5)  
Antibodies location Mean (s.d.) staining intensity score P-value
CD20
Diffuse1.50 (1.51)1.40 (1.14)1.0000
Around2.75 (1.28)0.8 (1.10) 0.0187
Inside1.13 (1.36)0.20 (0.45)0.2090
Foci3.63 (0.52)3.40 (0.89)0.7339
    
CD3
Diffuse1.50 (1.41)1.60 (1.52)0.9381
Around3.25 (0.71)1.80 (1.30) 0.0362
Inside1.75 (1.49)0.20 (0.45) 0.0437
Foci3.00 (0.76)3.20 (0.45)0.6134
    
CD4
Diffuse0.88 (1.64)0.60 (1.34)0.7659
Around2.75 (1.49)1.80 (1.64)0.1852
Inside0.75 (1.04)0.40 (0.55)0.6737
Foci2.50 (1.31)2.80 (0.84)0.9364
    
CD8
Diffuse2.13 (1.36)0.80 (1.79)0.2037
Around2.88 (1.25)2.60 (1.52)0.7362
Inside1.75 (1.04)2.80 (0.45) 0.0503
Foci2.38 (1.69)2.00 (1.87)0.7045
    
CD68
Diffuse0.88 (1.25)2.40 (1.34) 0.0467
Around2.13 (1.81)0.80 (1.79)0.2590
Inside0.88 (1.25)1.20 (1.10)0.6215
Foci0.25 (0.71)0.00 (0.00)0.4292
    
PS100
Diffuse1.50 (1.51)2.20 (1.30)0.3635
Around2.25 (1.58)2.60 (1.52)0.6471
Inside1.50 (1.85)0.40 (0.89)0.2418
Foci1.75 (1.91)2.60 (1.52)0.5323
    
CD1a
Diffuse1.50 (0.93)1.20 (0.45)0.4666
Around0.88 (0.83)0.40 (0.89)0.2590
Inside0.63 (0.74)0.20 (0.45)0.2693
Foci0.00 (0.00)0.00 (0.00) 
    
HLA-DR
Diffuse2.00 (1.31)2.00 (1.22)0.8750
Around3.13 (1.36)2.80 (0.45)0.1454
Inside1.75 (1.04)1.40 (1.34)0.6471
Foci2.50 (1.31)2.60 (0.55)1.0000
    
CD56 a
Diffuse0.75 (1.16)0.40 (0.89)0.5306
Around2.25 (1.67)1.00 (1.41)0.1460
Inside0.88 (0.99)0.00 (0.00)0.0714
Foci0.00 (0.00)0.40 (0.89)0.2059
    
NK1
Diffuse0.57 (1.13)1.00 (1.41)0.6282
Around3.00 (1.41)2.20 (0.84)0.1063
Inside1.29 (1.50)1.20 (1.30)1.0000
Foci2.71 (1.38)2.00 (1.22)0.2332
    
TiA1
Diffuse0.63 (1.19)1.00 (1.41)0.5902
Around3.13 (1.36)1.60 (1.52) 0.0456
Inside1.50 (1.20)0.60 (0.89)0.1697
Foci0.50 (1.41)0.60 (1.34)0.8160
    
Granzyme B
Diffuse0.50 (1.07)0.20 (0.45)0.7659
Around2.00 (1.60)0.60 (0.89)0.1107
Inside0.63 (1.06)0.00 (0.00)0.1366
Foci0.25 (0.71)0.80 (1.30)0.2762

For diffuse/around/inside/foci, scores range from 0 to 4.

aStaining with CD56 was less intense and difficult to quantify.

Significant if P<0.01 (multiple testing adjustment). Bold values signify their importance in the results and the discussion.

HER2 expression on residual tumour cells

At the time of surgery, HER2 overexpression was unaffected by trastuzumab treatment, with pre- and posttreatment biopsies demonstrating strong A485 staining on tumour cell membranes.

DISCUSSION

Approximately 20–30% of all breast cancers overexpress HER2 (Slamon et al, 1987; van de Vijver et al, 1988; Ross et al, 2003; Owens et al, 2004). Targeted treatment of HER2-positive metastatic breast cancer (MBC) with single-agent trastuzumab demonstrates favourable efficacy (Cobleigh et al, 1999; Vogel et al, 2002), and efficacy is enhanced by combination with cytotoxic chemotherapy (Slamon et al, 2001; Marty et al, 2005). Indeed, combination treatment with trastuzumab and cytotoxic chemotherapy is now used as standard therapy for HER2-positive MBC. Trastuzumab is thought to have a diverse and complex mechanism of action. As trastuzumab is a monoclonal antibody that binds to the surfaces of HER2-overexpressing cancer cells, it has been postulated that ADCC may play an important role in the mechanism of action of this drug (Cooley et al, 1999; Clynes et al, 2000; Carson et al, 2001; Repka et al, 2003; Gennari et al, 2004). The current in vivo study was undertaken to analyse the potential role of different immune cells in the clinical response to trastuzumab.

Pre- and postoperative breast tissue samples were obtained from patients with HER2-overexpressing advanced breast cancer participating in a clinical trial of a neoadjuvant regimen incorporating trastuzumab and docetaxel. This treatment strategy is associated with a high pathologic response rate (Coudert et al, 2005), which is in accordance with the good efficacy previously reported for the combination of paclitaxel and trastuzumab in this setting (Bines et al, 2003; Burstein et al, 2003; Schiffhauer et al, 2003; Van Pelt et al, 2003; Baselga et al, 2004). In order to discount the effects of intratumoural immune cell modifications that may be induced by conventional chemotherapy drugs, the control group comprised tumours from patients treated with two different PST regimens (including and excluding docetaxel). Treatment and control groups were matched in respect of pathologic response to eliminate the effects of intratumoral immune cell modifications induced by the response itself. This is the first time a comparison of this type has been reported.

The results of this study demonstrate that the inclusion of trastuzumab in the PST regimen influences the number and topography of various immune cells, including T and B lymphocytes and NK cells, in tumour infiltrates. Natural killer cells are able to kill cells that are coated with an antibody via an ADCC mechanism (Clynes et al, 2000). The presence of increased numbers of NK cells in tumour infiltrates after trastuzumab treatment, as well as the presence of cytotoxic proteins such as Granzyme B, lends support to a role for NK cells in trastuzumab-induced tumour regression. Increased numbers of NK cells are also seen in tumours demonstrating an incomplete but pathologically important response (TB) compared with those showing a poor or absent pathologic response (TC or TD). The persistence of HER2 overexpression confirms that trastuzumab-mediated ADCC is a feasible mechanism of action for the drug.

Two in vivo pilot studies have evaluated the potential role of ADCC in the mechanism(s) of action of trastuzumab. Repka et al (2003) demonstrated that treatment with a combination of trastuzumab and interleukin-2 led to NK cell expansion and NK cell-mediated ADCC against HER2-overexpressing cells. Additionally, they showed that serum from treated patients had residual ADCC activity 2–8 weeks after the last trastuzumab injection. Gennari et al (2004) showed that peripheral blood mononuclear cells of trastuzumab-treated patients demonstrated in vitro cytopathic activity against HER2-overexpressing cells, with ADCC activity more pronounced in tumours demonstrating a good response to treatment compared with those exhibiting a poor response. In common with the present study, Gennari did not observe downregulation of HER2 expression after treatment, although they were able to demonstrate that residual tumour cells were still coated with trastuzumab at the time of the surgery as well as an increase in NK-rich lymphoid infiltration, but were unable to attribute this increase to the type of treatment or to the regression itself.

Further support for a role for ADCC in the mechanism of action of trastuzumab has emerged from in vivo xenograft (Clynes et al, 2000) and in vitro studies (Cooley et al, 1999; Carson et al, 2001; Kubo et al, 2003), which have demonstrated that NK cells are able to kill trastuzumab-coated HER2-overexpressing cells via a FcγRIII receptor (CD16)-mediated ADCC mechanism. Yamaguchi et al (2005) also demonstrated that lymphokine-activated killer cell cytotoxic activity against HER2-positive breast cancer cell lines MDA-MB453 and ZR75-1 was significantly increased in the presence of 10 nM trastuzumab. These data, together with the current data, lend support to the evaluation of combination therapy with trastuzumab and immunomodulatory agents, such as interleukin-2 (Fleming et al, 2002; Repka et al, 2003), as well as the construction of bispecific antibodies targeting HER2 and CD16 (Shahied et al, 2004).

Trastuzumab plus docetaxel is an approved and well-tolerated anticancer regimen that is used worldwide for the treatment of HER2-positive MBC. Taxanes, especially docetaxel, lead to increased serum concentrations of some cytokines and enhancement of NK cell activity (Tsavaris et al, 2002). The current study confirms that NK cytotoxicity via ADCC is probably one of the mechanisms of action of trastuzumab and demonstrates increased numbers of NK cells in tumours treated with docetaxel and trastuzumab compared with docetaxel alone. These findings may partially explain the synergistic activity of trastuzumab and docetaxel in the treatment of HER2-positive breast cancer and the excellent clinical outcomes afforded by this combination. In the TAXHER01 study (Coudert et al, 2005), tumours that were centrally confirmed to be HER2 positive displayed a pCR of 54%. This is superior to that observed with non-trastuzumab-containing neoadjuvant regimens in unselected patient populations. The results of this immunohistochemical study may also have implications for the design of future clinical trials involving trastuzumab. Perceived trastuzumab activity may be damaged by association with therapies that have immunosuppressive properties. An interesting area for future investigation could be combination therapy with trastuzumab, chemotherapy and immunomodulators, for example, co-administration of NK cells and/or cytokine injections.

Acknowledgments

This work was presented in part at the 96th AACR Annual Meeting, April 2005, and was supported in part by the Comités de Côte d'Or et de la Nièvre de la Ligue contre le Cancer and by F Hoffmann-La Roche Ltd.

References
  • Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C (2004) Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 31: 51–57 [Abstract] [Google Scholar]
  • Bines J, Murad A, Lago S, Ferrari B, Andrade J, Filho EA (2003) Weekly docetaxel (Taxotere®) and trastuzumab (Herceptin®) as primary therapy in stage III HER-2 overexpressing breast cancer – a Brazilian multicenter study. Breast Cancer Res Treat 82(Supplement 1): S56 (abstract 243) [Google Scholar]
  • Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21: 46–53 [Abstract] [Google Scholar]
  • Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676–3685 [Abstract] [Google Scholar]
  • Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31: 3016–3025 [Abstract] [Google Scholar]
  • Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumour targets. Nat Med 6: 443–446 [Abstract] [Google Scholar]
  • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648 [Abstract] [Google Scholar]
  • Cooley S, Burns LJ, Repka T, Miller JS (1999) Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27: 1533–1541 [Abstract] [Google Scholar]
  • Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Moluçon C, Tubiana N, Causeret S, Misset J-L, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P (2005) Preoperative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2005 Dec 6 [Epub ahead of print] [Abstract]
  • Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson III WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ (2002) A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 8: 3718–3727 [Abstract] [Google Scholar]
  • Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumours overexpressing HER2. Clin Cancer Res 10: 5650–5655 [Abstract] [Google Scholar]
  • Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049–1056 [Abstract] [Google Scholar]
  • Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165–184 [Abstract] [Google Scholar]
  • Jackson JG, St Clair P, Sliwkowski MX, Brattain MG (2004) Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601–2609 [Abstract] [Google Scholar]
  • King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976 [Abstract] [Google Scholar]
  • Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M (2003) Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res 23: 4443–4449 [Abstract] [Google Scholar]
  • Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast Jr RC (2003) The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumour growth inhibition. J Biol Chem 278: 23441–23450 [Abstract] [Google Scholar]
  • Luporsi E, Vanlemmens L, Coudert B (2000) Six cycles of FEC 100 vs six cycles of Epirubicin/Docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: results of a randomized phase II trial of GIREC SO1 (Highlights from the 36th Annual ASCO Meeting). Cancer Conf Highlights 4: 2–4 [Google Scholar]
  • Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274 [Abstract] [Google Scholar]
  • Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC (2005) Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23: 2460–2468 [Abstract] [Google Scholar]
  • Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744–4749 [Abstract] [Google Scholar]
  • Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63–69 [Abstract] [Google Scholar]
  • Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241–2251 [Abstract] [Google Scholar]
  • Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS (2003) Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 9: 2440–2446 [Abstract] [Google Scholar]
  • Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307–325 [Abstract] [Google Scholar]
  • Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297–306 [Abstract] [Google Scholar]
  • Schiffhauer LM, Griggs JJ, Ahrendt GM, Sorbero ME (2003) Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Am Soc Clin Oncol 22: 242 (abstract 969) [Google Scholar]
  • Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM (2004) Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumour lysis when placed in a divalent tumour antigen-binding format. J Biol Chem 279: 53907–53914 [Abstract] [Google Scholar]
  • Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20: 3628–3636 [Abstract] [Google Scholar]
  • Singletary SE, Greene FL (2003) Breast task force: revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21: 53–59 [Abstract] [Google Scholar]
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182 [Abstract] [Google Scholar]
  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712 [Abstract] [Google Scholar]
  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792 [Abstract] [Google Scholar]
  • Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87: 21–27 [Europe PMC free article] [Abstract] [Google Scholar]
  • van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239–1245 [Abstract] [Google Scholar]
  • Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci Jr A, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4: 348–353 [Abstract] [Google Scholar]
  • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726 [Abstract] [Google Scholar]
  • Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumour action. Cancer Res 62: 4132–4141 [Abstract] [Google Scholar]
  • Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T (2005) HER2-specific cytotoxic activity of lympholine-activated killer cells in the presence of trastuzumab. Anticancer Res 25: 827–832 [Abstract] [Google Scholar]
Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Full text links 

Read article at publisher's site: https://doi.org/10.1038/sj.bjc.6602930

Read article for free, from open access legal sources, via Unpaywall: https://www.nature.com/articles/6602930.pdfUnpaywall

Citations & impact 

Impact metrics

337
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/228573
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/228573

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1038/sj.bjc.6602930

Supporting
Mentioning
Contrasting
10
314
1

Article citations

Go to all (337) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.